bioAffinity Technologies (BIAF) Equity Average (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Equity Average data on file, last reported at $5.5 million in Q1 2026.

• Equity Average for Q1 2026 came in at $5.5 million, up 170.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 170.67% YoY), and the FY2025 annual result was $4.9 million, up 32.48% from the prior year.
• Equity Average slipped to $5.5 million in Q1 2026 per BIAF's latest filing, from $8.1 million in the prior quarter.
• Over five years, Equity Average peaked at $11.8 million in Q4 2022 and troughed at -$16.8 million in Q2 2022.
• A 5-year average of $2.6 million and a median of $4.3 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average soared 460.38% in 2023, then sank 108.02% in 2025.
• A 5-year view of Equity Average shows it stood at $11.8 million in 2022, then tumbled by 49.88% to $5.9 million in 2023, then sank by 51.7% to $2.9 million in 2024, then surged by 182.71% to $8.1 million in 2025, then slumped by 32.39% to $5.5 million in 2026.
• Business Quant data shows BIAF's Equity Average at $5.5 million in Q1 2026, $8.1 million in Q4 2025, and $3.4 million in Q3 2025.